HCAT Health Catalyst
- 6.950
- -0.080-1.14%
- 6.950
- 0.0000.00%
Health Catalyst News
Analysts Have Conflicting Sentiments on These Healthcare Companies: Curis (CRIS), Health Catalyst (HCAT) and Innate Pharma SA (OtherIPHYF)
Health Catalyst First Quarter 2024 Earnings: EPS Misses Expectations
Health Catalyst Inc (HCAT) Q1 2024 Earnings: Modest Revenue Growth and Strategic Financial ...
Health Catalyst | 10-Q: Quarterly report
Health Catalyst Is Maintained at Overweight by Wells Fargo
Health Catalyst Is Maintained at Overweight by Wells Fargo
Wells Fargo: Maintaining the Health Catalyst (HCAT.US) rating, adjusted from an increase in holdings to an increase rating, and the target price was adjusted from $14.00 to $13.00.
Wells Fargo: Maintaining the Health Catalyst (HCAT.US) rating, adjusted from an increase in holdings to an increase rating, and the target price was adjusted from $14.00 to $13.00.
Wells Fargo Maintains Overweight on Health Catalyst, Lowers Price Target to $13
Wells Fargo analyst Stan Berenshteyn maintains Health Catalyst with a Overweight and lowers the price target from $14 to $13.
Health Catalyst Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 103.12% Wells Fargo $14 → $13 Maintains Overweight 04/10/2024 150% Cantor Fitzgerald → $16 Reit
Earnings Call Summary | Health Catalyst(HCAT.US) Q1 2024 Earnings Conference
The following is a summary of the Health Catalyst, Inc. (HCAT) Q1 2024 Earnings Call Transcript:Financial Performance:Health Catalyst reported Q1 2024 total revenue of $74.7 million, and adjusted EBIT
Strong Q1 Performance and Strategic Ignite Platform Launch Underpin Buy Rating for Health Catalyst (HCAT)
Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT), Bluebird Bio (BLUE) and Viatris (VTRS)
Buy Rating Affirmed for Health Catalyst Amid Solid Growth and Strategic Financial Management
KeyBanc Keeps Their Hold Rating on Health Catalyst (HCAT)
Health Catalyst (HCAT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Health Catalyst Sees FY24 Revenue $304.0M-$312.0M Vs $308.685M Est.
Health Catalyst Sees FY24 Revenue $304.0M-$312.0M Vs $308.685M Est.
Health Catalyst Sees Q2 2024 Revenue $73.5M-$76.5M Vs $75.554M Est.
Health Catalyst Sees Q2 2024 Revenue $73.5M-$76.5M Vs $75.554M Est.
Health Catalyst (HCAT.US): The 2024 Q1 financial report achieved revenue of US$74.723 million, prior value of US$73.868 million, expected value of US$74.8 million; earnings per share were US$0.05, previous value was US$0.05, and expected value was US$0.03
Health Catalyst (HCAT.US): The 2024 Q1 financial report achieved revenue of US$74.723 million, prior value of US$73.868 million, expected value of US$74.8 million; earnings per share were US$0.05, previous value was US$0.05, and expected value was US$0.03.
Earnings Flash (HCAT) HEALTH CATALYST Posts Q1 EPS $0.05, Vs. Street Est of $0.03
04:17 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (HCAT) HEALTH CATALYST Posts Q1 EPS $0.05, vs. Street Est of $0.03
Health Catalyst 1Q Loss $20.6M >HCAT
Health Catalyst 1Q Loss $20.6M >HCAT
Press Release: Health Catalyst Reports First Quarter 2024 Results
Health Catalyst Reports First Quarter 2024 Results SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics t
Analysis
Price Target
No Data
